ArticleCell communication and signaling : CCS2025

Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression.

Jae-Min Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.